Intuitive Surgical, Inc. $ISRG Shares Sold by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA reduced its stake in Intuitive Surgical, Inc. by 9.3%, holding 116,324 shares valued at approximately $53.24 million.
• A number of institutional investors have increased their positions in Intuitive Surgical, with Chilton Capital Management LLC increasing its holdings by 614.3% in the first quarter.
• Analysts have maintained a largely positive outlook on Intuitive Surgical, with thirteen analysts rating it as a Buy, despite varying target price adjustments.

Banque Transatlantique SA cut its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 9.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,324 shares of the medical equipment provider's stock after selling 11,961 shares during the period. Intuitive Surgical accounts for 1.0% of Banque Transatlantique SA's portfolio, making the stock its 19th largest position. Banque Transatlantique SA's holdings in Intuitive Surgical were worth $53,241,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in ISRG. Chilton Capital Management LLC raised its holdings in Intuitive Surgical by 614.3% in the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 43 shares in the last quarter. Global Financial Private Client LLC raised its holdings in Intuitive Surgical by 253.3% in the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 38 shares in the last quarter. Elite Financial Inc. acquired a new stake in Intuitive Surgical in the first quarter valued at $26,000. LFA Lugano Financial Advisors SA acquired a new stake in Intuitive Surgical in the first quarter valued at $30,000. Finally, TD Capital Management LLC raised its holdings in Intuitive Surgical by 300.0% in the first quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 45 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Mark Brosius sold 216 shares of the company's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the sale, the senior vice president owned 907 shares of the company's stock, valued at $510,740.77. This represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gary S. Guthart sold 29,360 shares of the company's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the completion of the sale, the insider directly owned 19,827 shares of the company's stock, valued at $9,368,059.23. The trade was a 59.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,769 shares of company stock valued at $21,532,536 over the last 90 days. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $469.07 on Wednesday. The company has a 50-day simple moving average of $498.54 and a 200-day simple moving average of $515.81. The firm has a market capitalization of $168.15 billion, a P/E ratio of 65.42, a P/E/G ratio of 4.96 and a beta of 1.61. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company's quarterly revenue was up 21.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.78 earnings per share. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Wall Street Zen upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Truist Financial boosted their target price on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Citigroup reiterated a "buy" rating and set a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Zacks Research lowered shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 20th. Finally, Evercore ISI boosted their target price on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Thirteen analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.